Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : CAVALRY'S SHORT BUSTERS - MAGIC EIGHTBALLS PICKS -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (1453)	11/6/1998 7:23:00 AM
From: Henry Niman	Respond to of 1637

GERN is reporting growth of stem cells in vitro. It is being widely covered (2 NY Times articles, WSJ, and front page of many newspapers). Could produce an ENMD type response this morning. Details linked to the New Therapeutics table at biocognizance.com

To: JEB who wrote (1453)	11/6/1998 5:04:00 PM
From: Cavalry	Read Replies (2) \| Respond to of 1637

you couldnt post that before the market closed yesterday, wow gern what a roller coaster ride you guys had today know gern is heavily shorted down from $30 to $16, problem is they are even farther from marketing anything than enmd is. great day trade for next week or so, something for everyone shorts and longs cav ps funny part is when i fell for cygs thought they might have deal going with gern, gern thread and gern ir had never heard of cygs, this should have been the first tipoff for me that cygs is a pos.